Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin in Treating Children With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic or unresectable solid tumors that are not amenable to standard treatment~  * Histological confirmation not required for brain stem tumors~* No known brain metastases~* No leukemia~PATIENT CHARACTERISTICS:~Age:~* 21 and under~Performance status:~* ECOG 0-2 OR~* Lansky 50-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm\^3 (except with marrow involvement)~* Hemoglobin at least 8 g/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin 0.2-1.4 mg/dL~* AST/ALT no greater than 3 times upper limit of normal~Renal:~* Creatinine normal for age OR~* Creatinine clearance at least 50 mL/min~* Electrolytes, calcium, and phosphorus normal~Cardiovascular:~* No symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~* No active graft-vs-host disease (GVHD)~* No allergy to platinum compounds or antiemetics~* No uncontrolled concurrent illness or infection~* No evidence of neuropathy~* Blood sugar normal~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 1 week since prior hematopoietic growth factors~* At least 3 months since prior stem cell transplantation and recovered~Chemotherapy:~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea)~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 6 weeks since prior extensive radiotherapy to significant marrow-containing compartment~* At least 6 months since prior craniospinal radiotherapy; total abdominal, pelvic, or extensive lung radiotherapy; or mantle and Y-port radiotherapy~* At least 6 months since prior total body irradiation~Surgery:~* Not specified~Other:~* No concurrent therapy for GVHD~* No other concurrent anticancer investigational or commercial agents~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).